The SH2 domain-containing protein tyrosine phosphatase SHP-1 is expressed widely in the hematopoietic system. SHP-1 has been shown to negatively control signal transduction from many cytokine receptors by direct docking to either the receptor itself, or to members of the Jak family of tyrosine kinases which are themselves part of the receptor complex. 
Introduction
Granulocyte colony-stimulating factor (G-CSF) is a major regulator of neutrophilic granulocyte production. [1] [2] [3] [4] Its actions are mediated via a specific cell-surface receptor, the G-CSF-R, which forms homo-oligomeric complexes upon ligand binding. 5 Like other members of the hematopoietin receptor superfamily, the G-CSF-R lacks intrinsic tyrosine kinase activity but activates numerous cytoplasmic tyrosine kinases and signaling cascades. 2, 5, 6 Important signaling molecules downstream of the G-CSF-R include certain members of the Janus tyrosine kinase (Jak) and signal transducer and activator of transcription (STAT) families of proteins, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] the Src kinases p55
Lyn and p56 /59 Hck , [17] [18] [19] and components of the p21 ras /Raf/MAPK pathway.
carboxyl terminus, predominantly expressed in hematopoietic cells. [24] [25] [26] [27] [28] Motheaten and viable motheaten mice have mutations in their SHP-1 gene and are characterized by increased myelopoiesis, as well as hypersensitivity to extracellular stimuli and heightened phosphorylation in their hematopoietic cells. [29] [30] [31] [32] [33] In addition, these mice show an accumulation of morphologically and phenotypically immature granulocytes. 30, 34, 35 However, whether these effects were due to aberrant G-CSF-R signaling remained unknown.
SHP-1 has been shown to bind directly to a number of tyrosine-phosphorylated receptors via its SH2 domains, including the erythropoietin receptor (EpoR), interleukin-2 receptor (IL-2R), interleukin-3 receptor (IL-3R), and the receptor for stem cell factor (c-Kit). [36] [37] [38] [39] [40] [41] Recruitment of SHP-1 in this manner facilitates the down-modulation of tyrosine phosphorylation and mitogenic signaling from the respective receptors. 36, [39] [40] [41] However, other studies have shown that SHP-1 can also interact directly with members of the Jak kinase family, including Tyk2 and Jak2, to modulate both their tyrosine phosphorylation and activity, 42, 43 or to STAT proteins themselves. 44 Myeloid 32D cells have provided a useful model for studying the regulation of granulocytic development. Stimulation of these cells with G-CSF produces transient proliferation followed by differentiation into mature neutrophilic granulocytes in response to G-CSF. 16, 45 In this study, we sought to identify key molecules that might participate in the switch from proliferation to differentiation in these cells. We show that SHP-1 is up-regulated following G-CSF stimulation, with kinetics suggestive of a role for this protein in the termination of the proliferative phase of these cells. However, enforced expression of wild-type and mutant SHP-1 in 32D cells revealed not only a negative role for SHP-1 in proliferation, but also a positive role in differentiation mediated by G-CSF. Finally, we show that SHP-1 impacts directly on G-CSF-R signaling, but that these effects are not mediated by direct docking to the activated receptor.
Materials and methods

Cell culture
The subline of the IL-3-dependent murine myeloid cell line 32D.cl3, called 32D.cl8.6, 16 and the IL-3-dependent murine pro-B cell line, Ba/F3 46 were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and 10 ng/ml of murine IL-3, at 37°C and 5% CO 2 .
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the WT and tyrosine-null mutant (mO) G-CSF-R. 15 Empty pBabe vector and pBabe expression constructs of wild-type and catalytically inactive (C453S) SHP-1 (SHP-1 wt and SHP-1 mut , respectively) were linearized by PvuI digestion and transfected into these 32D and Ba/F3 clones by electroporation. After 48 or 24 h of incubation, respectively, cells were selected with Puromycin (Gibco-BRL, Breda, The Netherlands) at concentrations of 1.0 and 1.25 g/ml, respectively, with multiple clones expanded for further analysis.
Analysis of G-CSF-R expression
To check G-CSF-R expression levels, cells were incubated at room temperature for 60 min with 10 g/ml of biotinylated mouse anti-human G-CSF-R monoclonal antibody LMM741 (PharMingen, San Diego, CA, USA), then at 4°C for 60 min sequentially with 5 g/ml of PE-conjugated streptavidin, 5 g/ml of biotinylated anti-streptavidin antibody, and finally 2 g/ml of PE-conjugated streptavidin, with washing between each antibody step. Samples were analyzed by flow cytometry using a FACScan (Becton Dickinson, San Jose, CA, USA). Only cell lines that had maintained homogeneous G-CSF-R expression were selected for further analysis.
Preparation of cell lysates and Western blotting
To obtain cell lysates, cells were pelletted, washed with icecold phosphate-buffered saline (PBS), and lysed by incubation for 30 min at 4°C in pTyr lysis buffer (1% Triton X-100, 100 mM NaCl, 50 mM Tris-HCl, pH 8.0, 0.1 mM Na 3 VO 4 , 1 mM DTT, 1 mM Pefabloc SC, 50 g/ml aprotinin, 50 g/ml leupeptin, 50 g/ml bacitracin) followed by centrifugation at 13 000 g for 15 min. The soluble proteins were mixed with sample buffer, separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred on to nitrocellulose (0.2 m; Schleicher & Schuell, Dassel, Germany). Filters were blocked by incubation in TBST (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.05% (v/v) Tween-20) containing 0.6% (w/v) BSA. Antibodies used for Western blotting were anti-SHP-1 (No. P17320, Transduction Laboratories, Lexington, KY, USA) and anti-SHP-2 (sc-280, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and were diluted in TBST containing 0.6% (w/v) BSA. After washing with TBST, immune complexes were detected with horseradish peroxidase-conjugated species-specific antiserum (DAKO, Glostrup, Denmark), followed by enhanced chemiluminescence reaction (DuPont, Boston, MA, USA). In some instances, membranes were stripped in 62.5 mM Tris-HCl pH 6.7, 2% SDS and 100 mM ␤-mercaptoethanol at 50°C for 30 min, reblocked, washed, and reprobed.
Northern blot analysis
RNA was extracted from cells using Ultraspec II (Biotecx Laboratories, Houston, TX, USA), separated on agarose-formaldehyde gels and transferred to Hybond N + filters (Amersham Life Sciences, Amersham, UK) according to the manufacturers' instructions. Probes were a 1 kb BamHI-BglII fragment from murine SHP-1 and an 0.8 kb PCR fragment of murine GAPDH which were 32 P-labeled by random priming (Boehringer, Mannheim, Germany).
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Cell proliferation and morphological analysis
To determine proliferation, cells were incubated at an initial density of 1-2 × 10 5 cells/ml in 10% FCS/RPMI medium supplemented with 100 ng/ml of human G-CSF, 10 ng/ml of murine IL-3, or without growth factors. The medium was replenished every 1-2 days, and the cell densities were adjusted to 1-2 × 10 5 cells/ml. Viable cells were counted on the basis of trypan blue exclusion. To analyze the morphological features, cells were spun onto glass slides and examined after May-Grü nwald-Giemsa staining. Studies were performed blinded and repeated multiple times by independent investigators.
Far Western analysis
The cytoplasmic domain of the human G-CSF-R (aa 630-813), and the SH2 domains of SHP-1 (aa 1-106; aa 107-267) and SHP-2 (aa 1-107; aa 110-215), were cloned into pET-15b (Novagen, Madison, WI, USA) and pGEX-2TK (Amersham Pharmacia Biotech -Benelux, Roosendaal, The Netherlands) respectively, utilizing standard PCR protocols to amplify the appropriate coding regions. For the production of tyrosinephosphorylated G-CSF-R cytoplasmic domain, the pET clone was introduced into the E. coli strain TKB1 (Stratagene, La Jolla, CA, USA), which contains an inducible tyrosine kinase. Fusion protein was produced according to the manufacturer's instructions, and subsequently 32 P-labeled with heart muscle kinase. For production of GST and GST-SH2 fusions, plasmids were transformed into XL-1 Blue (Stratagene), with proteins expressed and purified on glutathione-Sepharose 4B beads as described. 47 The purified proteins were electrophoresed on 10% SDS-PAGE gels, 48 and electrophoretically transferred to Hybond-C membranes (Amersham Pharmacia Biotech). The membranes were then processed through a denaturationrenaturation cycle 49 and probed with the 32 P-labeled G-CSF-R, as described.
19,50
Electrophoretic mobility shift assay (EMSA)
Cells were deprived of serum and factors for 4 h at 37°C in RPMI 1640 medium at a density of 1 × 10 6 per ml, and then stimulated with either RPMI 1640 medium alone or in the presence of 100 ng/ml human G-CSF. At different time points, 10 volumes of ice-cold phosphate-buffered saline (PBS) supplemented with 10 M Na 3 VO 4 were added. Cells were then pelletted and resuspended in ice-cold hypotonic buffer (20 mM HEPES pH 7.8, 20 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , 1 mM DTT, 1 mM EDTA, 1 mM EGTA, 0.2% Tween-20, 0.125 M okadaic acid, 1 mM Pefabloc SC, 50 g/ml aprotinin, 50 g/ml leupeptin, 50 g/ml bacitracin and 50 g/ml iodoacetamide). 51 Cells were vortexed for 10 s and the nuclei pelletted by centrifugation at 15 000 g for 30 s. Nuclear extracts were prepared by resuspension of the nuclei in highsalt buffer (hypotonic buffer with 420 mM NaCl and 20% glycerol) and extraction of proteins by rocking for 30 min at 4°C. Insoluble materials were removed by centrifugation at 4°C for 15 min at 15 000 g. Nuclear extracts of approximately 0.4 × 10 6 cells were incubated for 20 min at room temperature with 0.2 ng of 32 P-labeled double-stranded oligonucleotide (5-10 × 10 3 c.p.m.) and 2 g of poly(dI-dC) in 20 l of binding buffer (13 mM HEPES, pH 7.8, 80 mM NaCl, 3 mM NaF, 3 mM NaMoO 4 , 1 mM DTT, 0.15 mM EDTA, 0.15 mM EGTA and 8% glycerol). 52 The oligonucleotide probes used in this study were m67 (5Ј-CATTTCCCGTAAATC), a high-affinity mutant of the sis-inducible element (SIE) of the human c-fos gene, 53 which binds STAT1 and STAT3, and ␤-cas (5Ј-AGATTTCTAGGAATTCAATCC), derived from the 5Ј region of the ␤-casein gene, 54 which binds STAT5 and STAT1. The DNA-protein complexes were separated by electrophoresis on 5% polyacrylamide gels containing 5% glycerol in 0.25 × TBE. The gels were dried and subsequently analyzed by autoradiography.
Results
SHP-1 is up-regulated during G-CSF-induced granulocytic differentiation
We have previously shown that 32D cells expressing the wildtype (WT) G-CSF-R (32D[WT] cells) proliferate transiently in response to G-CSF, followed by terminal granulocytic differentiation into mature neutrophils. 16, 45 To explain the transition from the proliferative phase to the differentiation phase, we hypothesized that the levels of an important signaling molecule might be modulated by G-CSF treatment. Therefore, we examined the levels of a number of signaling molecules using Western blot analysis, including STAT3, STAT5, Shc, Grb2, PI3K, Hck and the tyrosine phosphatases SHP-1 and SHP-2. Of those proteins analyzed, only the SHP-1 protein showed increased levels in response to G-CSF-treatment (Figure 1a) . As a control the blot was stripped and re-probed with SHP-2 to confirm equal loading. Interestingly, Northern blot analysis revealed no similar induction of SHP-1 at the mRNA level (Figure 1b) .
SHP-1 enhances G-CSF-induced differentiation at the expense of proliferation in 32D cells
The (Figure 2b ). SHP-1 mut clones were also obtained, although these showed reduced expression at the protein level (Figure 2b ). However, Northern blot analysis confirmed expression of both exogenous and endogenous SHP-1 in these clones (Figure 2c ), which also showed functional differences to controls (see below).
To assess the effects of SHP-1 expression, these clones were compared to vector control transfectants 
STAT activation from the G-CSF-R is reduced by SHP-1
To investigate whether receptor signaling was directly affected by SHP-1, we analyzed STAT5 activation as a sensitive assay of receptor activation. 16 In addition, STAT5 appears to play a key role in G-CSF-induced mitogenesis. 55 
Tyrosine docking sites on the G-CSF-R are not required for the effects of SHP-1
Since SHP-1 wt affected G-CSF-R signaling, we analyzed whether it might directly associate with the activated G-CSF-R via its SH2 domains, as shown for a number of other receptors. 37, [39] [40] [41] To this end, we produced the cytoplasmic domain of the human G-CSF-R in a recombinant, tyrosine-phosphorylated form. This was 32 P-labeled and used in an in vitro binding assay on various GST-SH2 domain fusions, which had been immobilized on nitrocellulose ( Figure 5 ). The tyrosinephosphorylated receptor did not bind to either SH2 domain of SHP-1, although it bound strongly to the N-terminal SH2 domain of SHP-2, suggesting there is no direct docking of SHP-1 to the activated G-CSF-R.
To confirm that receptor tyrosines were not required for the effects of SHP-1, we also introduced SHP-1 wt into Ba/F3 cells expressing either wild-type G-CSF-R (Ba/F3[WT] cells), or a mutant of the G-CSF-R that lacks all of the cytoplasmic tyro- (Figure 6b ). These also showed inhibition of G-CSF-dependent growth (Figure 7) , indicating that the receptor tyrosines are not a prerequisite for the growth modulatory effects of SHP-1 on G-CSF signaling.
Discussion
We set out to identify key regulators of the switch from proliferation to differentiation in G-CSF-stimulated myeloid 32D cells. We showed firstly that SHP-1 is up-regulated at the protein level following G-CSF stimulation of these cells. The kinetics of this induction largely mirrored the slowdown of the proliferative phase, suggesting a possible role for SHP-1 in the shut-off of proliferation during the terminal differentiation of these cells. Introduction of SHP-1 wt and SHP-1 mut expression vectors into 32D and Ba/F3 cells provided clear evidence that SHP-1 acts as a direct negative regulator of G-CSF-mediated proliferation. Unexpectedly, it appears that SHP-1 also augments differentiation in our 32D cell model, suggesting that it may not merely function as a negative regulator of growth factor-induced mitogenesis, as other studies have suggested. Finally, we showed that receptor tyrosines were not required for SHP-1 to exert its modulatory effect on G-CSF-R signaling. This was supported by the lack of in vitro binding between the SH2 domains of SHP-1 and a recombinant, tyrosinephosphorylated G-CSF-R cytoplasmic domain.
Motheaten and viable motheaten mice, which possess mutations in the gene for SHP-1, show an increased number, size and sensitivity of CFU-GM colonies, and an increased proliferation of bone marrow cells in response to G-CSF. 30, 33 In addition, there is an accumulation of morphologically and phenotypically immature granulocytes, 30, 34, 35 implying a role for SHP-1 in granulocytic differentiation. However, it was unclear from these studies whether the abnormalities in the granulocytic compartment of motheaten mice were a consequence of aberrant G-CSF signaling, which would directly impact on granulocytic differentiation, or of dysregulation of the signaling of other cytokines, such as IL-3 and GM-CSF, which promote myeloid proliferation and might therefore indirectly affect granulocytic differentiation. Our data showing that granulocytic differentiation is associated with increased SHP-1 expression and, importantly, that increasing SHP-1 levels through ectopic expression augments G-CSF-induced granulocytic differentiation, provide the first evidence for a functional role of SHP-1 in directly regulating this process by modulating G-CSF-R signaling. Thus, the immaturity of the granulocytic cells in the SHP-1-deficient mice is likely due, at least in part, to a defect in the (G-CSF-R-mediated) differentiation-promoting activity of the phosphatase.
Tapley et al 33 have previously shown both enhanced proliferative responses and increased STAT activation from bone marrow cells of viable motheaten mice stimulated with G-CSF. These authors hypothesized that these results were simply due to the presence of more G-CSF-responsive precursor cells in the bone marrow of these animals, rather than a direct effect on G-CSF-R signaling. However, our data using clones overexpressing SHP-1 wt and SHP-1 mut provide clear evidence that SHP-1 acts as a direct regulator of G-CSF-mediated responses. Furthermore, the phenotype of the 32D[SHP-1 mut ] clone, showing enhanced proliferation and STAT activation in response to G-CSF, resembles that of bone marrow cells from viable motheaten mice. 33 Therefore, it appears that a deficiency in SHP-1 activity alone is sufficient to explain an enhancement of G-CSF signals in responsive cells; any increase in the number of G-CSF-responsive cells in viable motheaten mice would further accentuate this effect.
The G-CSF-mediated increase in SHP-1 protein levels seen in 32D cells was not reflected in a concomitant increase in the levels of SHP-1 mRNA, suggesting some form of post-tran- , as indicated. Serum-and growth factor-deprived cells were incubated at 37°C without factor (−), with 100 ng/ml G-CSF (+) for the times indicated. Nuclear extracts were prepared and incubated with 32 P-labeled double-stranded ␤-cas oligonucleotide probe. The positions and identities of the different STAT complexes 16 are shown.
Figure 5
Lack of interaction between SHP-1 and G-CSF-R in vitro. GST or GST-fusions of the SH2 domains indicated were separated on duplicate SDS-PAGE gels and either stained with Coomassie or transferred to nitrocellulose and subjected to Far Western blot analysis using 32 P-labeled, tyrosine-phosphorylated G-CSF-R cytoplasmic domain (G-CSF-R pY) as a probe. scriptional control is removed by G-CSF-stimulation. However, introduction of expression vectors is able to alleviate the observed regulation. We also examined SHP-1 levels in NB4 cells which were induced to differentiate into granulocytes by treatment with ATRA. In this case, levels of SHP-1 protein and mRNA were increased approximately two-fold within one day (data not shown). This not only suggests that alternate means to control SHP-1 expression are possible, but also supports our hypothesis that increasing SHP-1 expression levels is important in regulating granulocytic differentiation. Interestingly, it has been reported that differentiation of HL-60 cells into macrophages 57 or granulocytes 58 is also associated with increased SHP-1 expression, while lower levels of SHP-1 expression have been found in certain normal immature B cells. 59 Modulation of SHP-1 expression might, therefore, play a more general role in the differentiation of multiple hematopoietic lineages.
We also showed that the effects of SHP-1 on G-CSF-R signaling did not require receptor tyrosines, and that SHP-1 does not bind directly to the activated G-CSF-R. This is in agree-
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Figure 6
Expression of SHP-1 in Ba/F3 clones. ment with the data of Tapley et al, 33 showing that SHP-1 fails to associate with the G-CSF-R in co-immunoprecipitations. Thus, SHP-1 appears able to modulate G-CSF-R signaling in the absence of direct docking to the receptor itself. Presumably this is through recruitment to other components of the receptor complex, although extensive co-immunoprecipitation studies have failed to identify these protein(s) (data not shown).
Finally, while our data shows that SHP-1 augments differentiation -leading to both earlier and more complete differentiation -it remains unclear exactly how this is achieved. SHP-1 could have a positive regulatory role in control of differentiation signals themselves. Alternatively, SHP-1 may be
Figure 7
Effect of SHP-1 expression on growth of Ba/F3 clones. Growth of indicated Ba/F3 clones on 100 ng/ml G-CSF, expressed relative to growth on IL-3 being set at 100%. Data represent the mean and standard error for three clones of each. Solid bars, VEC clones; empty bars, SHP-1 wt clones; striped bars, SHP-1 mut clones.
important for cell survival, which could also contribute to the observed effects on differentiation. In support of this possibility, it was extremely difficult to isolate clones over-expressing the catalytically inactive mutant of SHP-1, and those which were obtained showed a clear tendency for reduced survival, especially at high cell densities (data not shown). However, irrespective of the exact mechanistic details, this represents a new role for SHP-1, previously regarded primarily as a negative regulator of mitogenic signaling.
Conclusion
In conclusion, we report that the SH2 domain-containing protein tyrosine phosphatase SHP-1 is upregulated at the protein level during the G-CSF-mediated granulocytic differentiation of myeloid 32D cells. Enforced expression of SHP-1 in these cells decreases proliferation and enhances differentiation, while transfection of a catalytically inactive mutant yields the opposite effect. Expression studies in cell lines harboring different G-CSF-R forms and in vitro binding analysis suggest that SHP-1 directly modulates G-CSF-mediated responses in hematopoietic cells via a mechanism that does not require direct docking to the activated G-CSF-R.
